Cover Image
市場調查報告書

PharmaPoint:心臟衰竭 (HF) - 全球醫藥品市場預測與市場分析

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025

出版商 GlobalData 商品編碼 296455
出版日期 內容資訊 英文 383 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:心臟衰竭 (HF) - 全球醫藥品市場預測與市場分析 PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025
出版日期: 2016年05月01日 內容資訊: 英文 383 Pages
簡介

主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 的心臟衰竭 (HF) 治療藥市場銷售額,預計從2015年的32億美元,到2025年擴大到115億美元。市場預計2015年∼2025年以13.5%的年複合成長率成長。

本報告提供心臟衰竭 (HF) 治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
  • 分類、病期分類系統
  • 症狀
  • 預後
  • QOL

第4章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
    • 美國
    • EU5個國家
    • 日本
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • 流行病學預測
    • 確診的發病數量
    • 確診的患者數
  • 議論
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 診斷、治療概要
  • 美國
  • EU5個國家
  • 日本

第6章 競爭評估

  • 概要
  • 藥物簡介
    • ACE抑制劑 (ACEI)
    • 血管收縮素受體阻斷劑 (ARB)
    • Entresto
    • 利尿劑
    • 乙型阻斷劑
    • Procoralan (Ivabradine)
    • 鹽皮質激素受體拮抗劑
    • 地高辛
    • 急性心臟衰竭 (AHF)的藥物療法

第7章 未滿足需求和機會

  • 概要
  • 缺乏對HF-PEF患者的治療方法
  • 缺乏對AHF的治療方法
  • 缺乏對利尿劑覺得阻力的AHF患者的治療方法
  • 缺乏對F腎功能障礙的患者的治療方法
  • 對有複數的合併症的患者的治療方法等

第8章 開發平台評估

  • 概要
  • 後期階段的臨床開發中的潛力藥物
  • 初期階段的臨床開發中的潛力藥物
  • 其他開發中的藥物

第9章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Novartis
    • Les Laboratoires Servier
    • Cardiorentis
    • Bayer (及 Merck. Co.)
    • Cytokinetics

第10章 市場預測

  • 全球市場
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第11章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC127PIDR

GlobalData estimates sales of Heart Failure (HF) therapeutics to be approximately $3.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The HF market will grow at a strong CAGR of 13.5% over the forecast period, reaching sales of $11.5B by 2025. The 7MM chronic HF market size in 2015 was $3.1B, and is expected to increase to $10.1B by 2025 at a CAGR of 12.7%. The US was the largest market for chronic HF therapies, contributing 61.2% of total sales in the base year. GlobalData expects uptake of Novartis' Entresto to be the strongest driver of the chronic HF and total HF markets in the 7MM, reaching peak sales of $5.9B in 2022. The acute HF market is expected to increase from just $188.1M in 2015 to $1.5B in 2025, at a CAGR of 23.0%. Japan dominated the acute HF market in the base year, 2015, accounting for 86.0% of market share. However, with the launch of several acute HF add-on therapies in the forecast period, the US will take over as the acute HF market leader, contributing 68.7% of sales to the acute HF market by 2025.

Highlights

Key Questions Answered

  • The level of unmet needs in the HF market is significantly high. Will the pipeline drugs fulfil these unmet needs of the market? Key Opinion Leaders (KOLs) interviewed by GlobalData provide insights and highlight opportunities for drug developers.
  • The HF market is crowded with cheap, generic, "me-too" drugs, making it a particularly difficult market to penetrate. The current late-stage pipeline consists of several chronic HF therapies, and three novel acute HF therapies. How will the market be impacted by the launch of these drugs? Which of the marketed and pipeline drugs will have the highest peak sales at the highest CAGR, and why?
  • Will Entresto become the new standard-of-care in the chronic HF market? What are the main barriers a new therapy faces when entering the HF market?

Key Findings

  • The major drivers for growth across the 7MM in the HF market during the forecast period will be the launch of the first-in-class angiotensin receptor blocker/neprilysin inhibitor (ARNi), Entresto, marketed by Novartis, as well as the launches of two acute HF therapies, Cardiorentis' ularitide and Novartis' serelaxin.
  • KOLs interviewed by GlobalData opined that Entresto has potential to replace ACE inhibitors as the first-line therapy for HF, however they expect this to occur towards the end of the forecast period.
  • In other interviews, KOLs highlighted that the greatest unmet need in the HF disease space is the need to develop efficacious therapies for HF with preserved ejection fraction (HF-PEF) and acute HF.
  • High cost of new drugs and the reluctance of cardiologists to prescribe these new drugs are the major barriers for growth in the HF market during the forecast period.

Scope

  • Overview of HF, both chronic and acute, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the chronic and acute HF therapeutics markets.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global HF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the HF therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HF therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the 7MM HF therapeutics market from 2015-2025.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
  • 3.2. Classification and Staging Systems
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiological Forecast for HF (2015-2025)
    • 4.5.1. Diagnosed Incident Cases
    • 4.5.2. Diagnosed Prevalent Cases
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Medical Devices
    • 5.1.4. Clinical Practice
  • 5.2. US
  • 5.3. 5EU
  • 5.4. Japan

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Drug Profiles
    • 6.2.1. Angiotensin-Converting Enzyme Inhibitors
    • 6.2.2. Angiotensin Receptor Blockers
    • 6.2.3. Entresto (sacubitril. valsartan)
    • 6.2.4. Diuretics
    • 6.2.5. Beta Blockers
    • 6.2.6. Procoralan (ivabradine)
    • 6.2.7. Mineralocorticoid Receptor Antagonists
    • 6.2.8. Digoxin
    • 6.2.9. Pharmacological Therapies for Acute HF

7. Unmet Needs and Opportunities

  • 7.1. Overview
    • 7.1.1. Acute HF. Target Opportunity Profile
    • 7.1.2. HF with Preserved Ejection Fraction. Target Opportunity Profile
    • 7.1.3. HF with Reduced Ejection Fraction. Target Opportunity Profile
  • 7.2. Lack of Therapies for HF with Preserved Ejection Fraction Patients
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Lack of Therapies for Acute HF
    • 7.3.1. Unmet Need
    • 7.3.2. Gap analysis
    • 7.3.3. Opportunity
  • 7.4. Lack of Therapies for Acute HF Patients Experiencing Diuretic Resistance
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Lack of Therapies for Patients with Renal Impairment
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Treatment of Patients with Multiple Comorbidities
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Enhanced Diagnosis and Preventative Therapies for Patients at Risk of Developing HF
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity
  • 7.8. Conducting Clinical Trials in Cohorts of Japanese Patients
    • 7.8.1. Unmet Need
    • 7.8.2. Gap Analysis
    • 7.8.3. Opportunity
  • 7.9. Use of Optimal Doses of HF Therapies
    • 7.9.1. Unmet Need
    • 7.9.2. Gap Analysis
    • 7.9.3. Opportunity
  • 7.10. Patient Compliance
    • 7.10.1. Unmet Need
    • 7.10.2. Gap Analysis
    • 7.10.3. Opportunity
  • 7.11. Early Detection and Treatment of Patients with Worsening Chronic HF
    • 7.11.1. Unmet Need
    • 7.11.2. Gap Analysis
    • 7.11.3. Opportunity
  • 7.12. Dynamic Management of Patients with HF
    • 7.12.1. Unmet Need
    • 7.12.2. Gap Analysis
    • 7.12.3. Opportunity
  • 7.13. Options for Advanced HF Patients Who Are Unable to Receive. Heart Transplant
    • 7.13.1. Unmet Need
    • 7.13.2. Gap Analysis
    • 7.13.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Late-Stage Clinical Development
    • 8.2.1. Serelaxin
    • 8.2.2. Ularitide
    • 8.2.3. Omecamtiv Mecarbil
    • 8.2.4. Vericiguat
    • 8.2.5. Finerenone
    • 8.2.6. Neucardin
    • 8.2.7. Revatio
  • 8.3. Promising Drugs in Early Stage Development
    • 8.3.1. CXL-1427
    • 8.3.2. Istaroxime
    • 8.3.3. Perhexiline Maleate
    • 8.3.4. TRV-027
  • 8.4. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Novartis
    • 9.3.2. Les Laboratoires Servier
    • 9.3.3. Cardiorentis
    • 9.3.4. Bayer (and Merck. Co.)
    • 9.3.5. Cytokinetics

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers. Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. UK
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Prevalent Chronic HF
    • 11.4.2. Diagnosed Incidence of Acute HF
    • 11.4.3. Percent Drug-Treated Patients
    • 11.4.4. Treatment of HF with Reduced Ejection Fraction Versus HF with Preserved Ejection Fraction
    • 11.4.5. Drugs Included in Each Therapeutic Class
    • 11.4.6. Launch and Patent Expiry Dates
    • 11.4.7. General Pricing Assumptions
    • 11.4.8. Individual Drug Assumptions
    • 11.4.9. Generic Erosion
    • 11.4.10. Pricing of Pipeline Agents
  • 11.5. Key Opinion Leaders Included in This Study
  • 11.6. Payers Included in This Study
  • 11.7. High-Prescribing Physician Survey
  • 11.8. About the Authors
    • 11.8.1. Author
    • 11.8.2. Contributing Author
    • 11.8.3. Therapy Area Director
    • 11.8.4. Epidemiologist
    • 11.8.5. Global Director of Therapy Analysis and Epidemiology
    • 11.8.6. Global Head of Healthcare
  • 11.9. About GlobalData
  • 11.10. Disclaimer

List of Tables

  • Table 1: Leading Causes of HF
  • Table 2: A Summary of the Compensatory Mechanisms in HF
  • Table 3: The Two Main Classification Systems in HF
  • Table 4: Typical Symptoms of HF
  • Table 5: Risk Factors and Comorbidities for HF
  • Table 6: NYHA Functional Classes I-IV
  • Table 7: ACCF/AHA Stages A, B, C, and D
  • Table 8: 7MM, Sources of Epidemiological Data Used for the Forecast of HF Diagnosed Incident Cases
  • Table 9: 7MM, Sources of Epidemiological Data Used for the Forecast of Chronic HF Diagnosed Prevalent Cases
  • Table 10: 7MM, Sources of Epidemiological Data Used for the Classification of Diagnosed Prevalent Cases of Chronic HF According to the NYHA Functional Classes I-IV
  • Table 11: 7MM, Sources of Epidemiological Data Used for Forecast of HF Diagnosed Incident Cases of Acute HF Hospitalizations
  • Table 12: 7MM, Sources Not Used in Epidemiological Analysis of HF
  • Table 13: 7MM, Diagnosed Incident Cases of HF, Ages ≥45 Years, Both Sexes, N, 2015-2025
  • Table 14: 7MM, Age-Specific Diagnosed Incident Cases of HF, Both Sexes, N (Row %), 2015
  • Table 15: 7MM, Sex-Specific Diagnosed Incident Cases of HF, Ages ≥45 Years, N (Row %), 2015
  • Table 16: 7MM, Diagnosed Incident Cases of Acute HF Hospitalizations, Ages ≥45 Years, Both Sexes, N, 2015-2025
  • Table 17: 7MM, Readmissions (Within Three Months) Post-Discharge After Acute HF Hospitalization Among Diagnosed Incident Cases of Acute HF, Ages ≥45 Years, Both Sexes, N, 2015-2025
  • Table 18: 7MM, Diagnosed Prevalent Cases of Chronic HF, Ages ≥45 Years, Both Sexes, N, 2015-2025
  • Table 19: 7MM, Age-Specific Diagnosed Prevalent Cases of Chronic HF, Both Sexes, N (Row %), 2015
  • Table 20: 7MM, Sex-Specific Diagnosed Prevalent Cases of Chronic HF, Ages ≥45 Years, N (Row %), 2015
  • Table 21: Guideline Recommended Tests for the Diagnosis of HF
  • Table 22: Common Factors that Precipitate Acute HF
  • Table 23: Treatment Guidelines for HF
  • Table 24: Comparison of the ACCF/AHA and NYHA HF Classification Systems
  • Table 25: Most Prescribed Drugs for HF by Class in the Global Markets, 2015
  • Table 26: Country Profile for HF - US
  • Table 27: Country Profile for HF - 5EU
  • Table 28: Country Profile for HF - Japan
  • Table 29: Efficacy of Enalapril
  • Table 30: Efficacy of Perindopril
  • Table 31: Global Sales Forecasts ($M) for ACE inhibitors, 2015-2025
  • Table 32: Global Sales Forecasts ($M) for ARBs, 2015-2025
  • Table 33: Product Profile - Entresto
  • Table 34: Efficacy of Entresto
  • Table 35: Safety of Entresto
  • Table 36: Entresto SWOT Analysis, 2015
  • Table 37: Global Sales Forecasts ($M) for Entresto, 2015-2025
  • Table 38: Global Sales Forecasts ($M) for Diuretics in the Chronic HF Market, 2015-2025
  • Table 39: Global Sales Forecasts ($M) for Loop Diuretics in the Acute HF Market, 2015-2025
  • Table 40: Global Sales Forecasts ($M) for Beta Blockers, 2015-2025
  • Table 41: Product Profile - Ivabradine
  • Table 42: Efficacy of Ivabradine
  • Table 43: Ivabradine SWOT Analysis, 2015
  • Table 44: Global Sales Forecasts ($M) for Procoralan/Corlanor (ivabradine), 2015-2025
  • Table 45: Global Sales Forecasts ($M) for MRAs, 2015-2025
  • Table 46: Global Sales Forecasts ($M) for Digoxin, 2015-2025
  • Table 47: Unmet Needs and Opportunities in HF
  • Table 48: Target Opportunity Profile for Acute HF
  • Table 49: Target Opportunity Profile for HF-PEF
  • Table 50: Target Opportunity Profile for HF-REF
  • Table 51: Chronic HF Comorbidities in the 7MM
  • Table 52: Comparison of Therapeutic Classes in Development for HF, 2015
  • Table 53: Product Profile - Serelaxin
  • Table 54: Efficacy of Serelaxin
  • Table 55: Serelaxin SWOT Analysis, 2015
  • Table 56: Global Sales Forecasts ($M) for Serelaxin, 2015-2025
  • Table 57: Product Profile - Ularitide
  • Table 58: Safety of Ularitide
  • Table 59: Ularitide SWOT Analysis, 2015
  • Table 60: Global Sales Forecasts ($M) for Ularitide, 2015-2025
  • Table 61: Product Profile - OM
  • Table 62: Efficacy of OM
  • Table 63: OM SWOT Analysis, 2015
  • Table 64: Global Sales Forecasts ($M) for OM (Chronic HF), 2015-2025
  • Table 65: Global Sales Forecasts ($M) for OM (Acute HF), 2015-2025
  • Table 66: Product Profile - Vericiguat
  • Table 67: Efficacy of Vericiguat
  • Table 68: Safety of Vericiguat
  • Table 69: Vericiguat SWOT Analysis, 2015
  • Table 70: Global Sales Forecasts ($M) for vericiguat, 2015-2025
  • Table 71: Product Profile - Finerenone
  • Table 72: Finerenone SWOT Analysis, 2015
  • Table 73: Product Profile - Neucardin
  • Table 74: Neucardin SWOT Analysis, 2015
  • Table 75: Product Profile - Revatio
  • Table 76: Efficacy of Revatio
  • Table 77: Revatio SWOT Analysis, 2015
  • Table 78: Drugs in Development, 2015
  • Table 79: Key Companies in the HF Market in the 7MM, 2015-2025
  • Table 80: Novartis' HF Portfolio Assessment, 2015
  • Table 81: Serviers' HF Portfolio Assessment, 2015
  • Table 82: Cardiorentis' HF Portfolio Assessment, 2015
  • Table 83: Bayer's HF Portfolio Assessment, 2015
  • Table 84: Cytokinetics' HF Portfolio Assessment, 2015
  • Table 85: Global Sales Forecasts ($M) for Chronic HF, 2015-2025
  • Table 86: Global Sales Forecasts ($M) for Acute HF, 2015-2025
  • Table 87: HF Global Market - Drivers and Barriers, 2015-2025
  • Table 88: Sales Forecasts ($M) for HF in the US, 2015-2025
  • Table 89: Key Events Impacting Sales for HF in the US, 2015-2025
  • Table 90: US HF Market - Drivers and Barriers, 2015-2025
  • Table 91: Sales Forecasts ($M) for HF in France, 2015-2025
  • Table 92: Key Events Impacting Sales for HF in France, 2015-2025
  • Table 93: French HF market - Drivers and Barriers, 2015-2025
  • Table 94: Sales Forecasts ($M) for HF in Germany, 2015-2025
  • Table 95: Key Events Impacting Sales for HF in Germany, 2015-2025
  • Table 96: Germany HF market - Drivers and Barriers, 2015-2025
  • Table 97: Sales Forecasts ($M) for HF in Italy, 2015-2025
  • Table 98: Key Events Impacting Sales for HF in Italy, 2015-2025
  • Table 99: Italy HF market - Drivers and Barriers, 2015-2025
  • Table 100: Sales Forecasts ($M) for HF in Spain, 2015-2025
  • Table 101: Key Events Impacting Sales for HF in Spain, 2015-2025
  • Table 102: Spain HF market - Drivers and Barriers, 2015-2025
  • Table 103: Sales Forecasts ($M) for HF in the UK, 2015-2025
  • Table 104: Key Events Impacting Sales for HF in the UK, 2015-2025
  • Table 105: UK HF market - Drivers and Barriers, 2015-2025
  • Table 106: Sales Forecasts ($M) for HF in Japan, 2015-2025
  • Table 107: Key Events Impacting Sales for HF in Japan, 2015-2025
  • Table 108: Japan HF market - Drivers and Barriers, 2015-2025
  • Table 109: Key Launch Dates
  • Table 110: Key Patent Expiries
  • Table 111: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: RAAS Mechanism of Action
  • Figure 2: 7MM, Diagnosed Incident Cases of HF, Ages ≥45 Years, Both Sexes, N, 2015-2025
  • Figure 3: 7MM, Diagnosed Incident Cases of HF by Age Group, Both Sexes, N, 2015
  • Figure 4: 7MM, Sex-Specific Diagnosed Incident Cases of HF, Ages ≥45 Years, N, 2015
  • Figure 5: 7MM, Age-Standardized Diagnosed Incidence of HF (Cases per 100,000 Population), Ages ≥45 Years, by Sex, 2015
  • Figure 6: 7MM, Diagnosed Incident Cases of HF Segmented by EF, Ages ≥45 Years, Both Sexes, N, 2015
  • Figure 7: 7MM, Diagnosed Incident Cases of HF Segmented by Ventricular Dysfunction, Ages ≥45 Years, Both Sexes, N, 2015
  • Figure 8: 7MM, Diagnosed Incident Cases of Acute HF Hospitalizations, Ages ≥45 Years, Both Sexes, N, 2015-2025
  • Figure 9: 7MM, Diagnosed Incident Cases of Acute HF Hospitalizations, Ages ≥45 Years, Both Sexes, N, 2015
  • Figure 10: 7MM, Readmissions (Within Three Months) Post-Discharge After Acute HF Hospitalization Among Diagnosed Incident Cases of Acute HF, Ages ≥45 Years, Both Sexes, N, 2015-2025
  • Figure 11: 7MM, Hospital Length Of Stay For Acute HF Hospitalization, Ages ≥45 Years, Both Sexes, Days, 2015
  • Figure 12: 7MM, Diagnosed Prevalent Cases of Chronic HF, Ages ≥45 Years, Both Sexes, N, 2015-2025
  • Figure 13: 7MM, Age-Specific Diagnosed Prevalent Cases of Chronic HF, Both Sexes, N, 2015
  • Figure 14: 7MM, Sex-Specific Diagnosed Prevalent Cases of Chronic HF, Ages ≥45 Years, N, 2015
  • Figure 15: 7MM, Age-Standardized Diagnosed Prevalence of Chronic HF (%), Ages ≥45 Years, by Sex, 2015
  • Figure 16: 7MM, Diagnosed Prevalent Cases of Chronic HF Segmented by EF, Ages ≥45 Years, Both Sexes, N, 2015
  • Figure 17: 7MM, Diagnosed Prevalent Cases of Chronic HF Segmented by NYHA Classes, Ages ≥45 Years, Both Sexes, N, 2015
  • Figure 18: 7MM, Diagnosed Prevalent Cases of Chronic HF Segmented by ACCF/AHA Stages, Ages ≥45 Years, Both Sexes, N, 2015
  • Figure 19: 7MM, Prevalent Cases of Comorbidities Among Diagnosed Prevalent Cases of Chronic HF, Both Sexes, Ages ≥45 Years, N, 2015
  • Figure 20: HF treatment based on ACCF/AHA Stage
  • Figure 21: HF - Phase II-III Pipeline, 2015
  • Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in HF, 2015-2025
  • Figure 23: Company Portfolio Gap Analysis in HF, 2015-2025
  • Figure 24: Global Sales for Chronic HF by Region, 2015-2025
  • Figure 25: Global Sales for Acute HF by Region, 2015-2025
  • Figure 26: Sales for Chronic HF in the US by Drug Class, 2015-2025
  • Figure 27: Sales for Acute HF in the US by Drug Class, 2025*
  • Figure 28: Sales for Chronic HF in France by Drug Class, 2015-2025
  • Figure 29: Sales for Acute HF in France by Drug Class, 2025*
  • Figure 30: Sales for Chronic HF in Germany by Drug Class, 2015-2025
  • Figure 31: Sales for Acute HF in Germany by Drug Class, 2025*
  • Figure 32: Sales for Chronic HF in Italy by Drug Class, 2015-2025
  • Figure 33: Sales for Acute HF in Italy by Drug Class, 2025*
  • Figure 34: Sales for Chronic HF in Spain by Drug Class, 2015-2025
  • Figure 35: Sales for Acute HF in Spain by Drug Class, 2025*
  • Figure 36: Sales for Chronic HF in the UK by Drug Class, 2015-2025
  • Figure 37: Sales for Acute HF in the UK by Drug Class, 2025*
  • Figure 38: Sales for Chronic HF in Japan by Drug Class, 2015-2025
  • Figure 39: Sales for Acute HF in Japan by Drug Class, 2015-2025
Back to Top